DocGo (DCGO) Competitors

$0.63 +0.01 (+1.91%)

Closing price 05/7/2026 04:00 PM Eastern

Extended Trading

$0.66 +0.03 (+3.96%)

As of 04:00 AM Eastern

DCGO vs. LFMD, AIRS, BNR, NAKA, and BDSX

Should you be buying DocGo stock or one of its competitors? The main competitors of DocGo include LifeMD (LFMD), AirSculpt Technologies (AIRS), Burning Rock Biotech (BNR), KindlyMD (NAKA), and Biodesix (BDSX). These companies are all part of the "healthcare" industry.

How does DocGo compare to LifeMD?

LifeMD (NASDAQ:LFMD) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

: LifeMD has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
: In the previous week, LifeMD had 11 more articles in the media than DocGo. MarketBeat recorded 13 mentions for LifeMD and 2 mentions for DocGo. DocGo's average media sentiment score of 0.00 beat LifeMD's score of -0.15 indicating that DocGo is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LifeMD
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
DocGo
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: LifeMD currently has a consensus target price of $9.14, suggesting a potential upside of 103.63%. DocGo has a consensus target price of $2.38, suggesting a potential upside of 274.66%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than LifeMD.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LifeMD
1 Sell rating(s)
1 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.67
DocGo
1 Sell rating(s)

3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.29
: 35.5% of LifeMD shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 18.4% of LifeMD shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: LifeMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LifeMD $194.05M 1.10 $14.35M $0.26 17.27
DocGo $322.20M 0.19 -$182.40M -$1.85 N/A
: LifeMD has a net margin of 2.37% compared to DocGo's net margin of -56.61%. DocGo's return on equity of -34.41% beat LifeMD's return on equity.
Company Net Margins Return on Equity Return on Assets
LifeMD 2.37% -176.40% -22.61%
DocGo -56.61% -34.41% -23.82%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.10	$14.35M	$0.26	17.27
DocGo	$322.20M	0.19	-$182.40M	-$1.85	N/A

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-176.40%	-22.61%
DocGo	-56.61%	-34.41%	-23.82%

Summary

LifeMD beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to AirSculpt Technologies?

AirSculpt Technologies (NASDAQ:AIRS) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

: AirSculpt Technologies has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
: In the previous week, DocGo had 1 more articles in the media than AirSculpt Technologies. MarketBeat recorded 2 mentions for DocGo and 1 mentions for AirSculpt Technologies. AirSculpt Technologies' average media sentiment score of 0.00 equaled DocGo'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AirSculpt Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DocGo
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: AirSculpt Technologies currently has a consensus target price of $6.00, suggesting a potential upside of 73.41%. DocGo has a consensus target price of $2.38, suggesting a potential upside of 274.66%. Given DocGo's stronger consensus rating and higher possible upside, analysts plainly believe DocGo is more favorable than AirSculpt Technologies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AirSculpt Technologies
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
DocGo
1 Sell rating(s)

3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.29
: 91.5% of AirSculpt Technologies shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 44.6% of AirSculpt Technologies shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: AirSculpt Technologies has higher earnings, but lower revenue than DocGo. AirSculpt Technologies is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AirSculpt Technologies $151.82M 1.61 -$11.67M -$0.19 N/A
DocGo $322.20M 0.19 -$182.40M -$1.85 N/A
: AirSculpt Technologies has a net margin of -7.68% compared to DocGo's net margin of -56.61%. AirSculpt Technologies' return on equity of -5.01% beat DocGo's return on equity.
Company Net Margins Return on Equity Return on Assets
AirSculpt Technologies -7.68% -5.01% -2.19%
DocGo -56.61% -34.41% -23.82%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AirSculpt Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82M	1.61	-$11.67M	-$0.19	N/A
DocGo	$322.20M	0.19	-$182.40M	-$1.85	N/A

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.68%	-5.01%	-2.19%
DocGo	-56.61%	-34.41%	-23.82%

Summary

AirSculpt Technologies beats DocGo on 9 of the 15 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

DocGo (NASDAQ:DCGO) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

: Burning Rock Biotech has a net margin of -10.27% compared to DocGo's net margin of -56.61%. Burning Rock Biotech's return on equity of -9.98% beat DocGo's return on equity.
Company Net Margins Return on Equity Return on Assets
DocGo -56.61% -34.41% -23.82%
Burning Rock Biotech -10.27% -9.98% -6.69%
: DocGo has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.
: Burning Rock Biotech has lower revenue, but higher earnings than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DocGo $322.20M 0.19 -$182.40M -$1.85 N/A
Burning Rock Biotech $77.16M 2.31 -$7.92M -$0.79 N/A
: 56.4% of DocGo shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 3.8% of DocGo shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: DocGo presently has a consensus target price of $2.38, indicating a potential upside of 274.66%. Given DocGo's stronger consensus rating and higher possible upside, equities analysts clearly believe DocGo is more favorable than Burning Rock Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DocGo
1 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.29
Burning Rock Biotech
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, DocGo had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for DocGo and 0 mentions for Burning Rock Biotech. DocGo's average media sentiment score of 0.00 equaled Burning Rock Biotech'saverage media sentiment score.
Company Overall Sentiment
DocGo Neutral
Burning Rock Biotech Neutral

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-56.61%	-34.41%	-23.82%
Burning Rock Biotech	-10.27%	-9.98%	-6.69%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.19	-$182.40M	-$1.85	N/A
Burning Rock Biotech	$77.16M	2.31	-$7.92M	-$0.79	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
DocGo	Neutral
Burning Rock Biotech	Neutral

Summary

Burning Rock Biotech beats DocGo on 8 of the 15 factors compared between the two stocks.

How does DocGo compare to KindlyMD?

DocGo (NASDAQ:DCGO) and KindlyMD (NASDAQ:NAKA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

: KindlyMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DocGo $322.20M 0.19 -$182.40M -$1.85 N/A
KindlyMD $1.82M 68.24 -$52.23M -$0.87 N/A
: DocGo presently has a consensus price target of $2.38, suggesting a potential upside of 274.66%. KindlyMD has a consensus price target of $0.75, suggesting a potential upside of 316.67%. Given KindlyMD's stronger consensus rating and higher possible upside, analysts clearly believe KindlyMD is more favorable than DocGo.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DocGo
1 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.29
KindlyMD
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
: In the previous week, DocGo had 1 more articles in the media than KindlyMD. MarketBeat recorded 2 mentions for DocGo and 1 mentions for KindlyMD. KindlyMD's average media sentiment score of 1.02 beat DocGo's score of 0.00 indicating that KindlyMD is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DocGo
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
KindlyMD
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: DocGo has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, KindlyMD has a beta of 17.12, indicating that its share price is 1,612% more volatile than the S&P 500.
: 56.4% of DocGo shares are owned by institutional investors. 3.8% of DocGo shares are owned by insiders. Comparatively, 24.5% of KindlyMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: DocGo has a net margin of -56.61% compared to KindlyMD's net margin of -2,866.57%. KindlyMD's return on equity of -16.11% beat DocGo's return on equity.
Company Net Margins Return on Equity Return on Assets
DocGo -56.61% -34.41% -23.82%
KindlyMD -2,866.57% -16.11% -11.25%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.19	-$182.40M	-$1.85	N/A
KindlyMD	$1.82M	68.24	-$52.23M	-$0.87	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KindlyMD	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-56.61%	-34.41%	-23.82%
KindlyMD	-2,866.57%	-16.11%	-11.25%

Summary

KindlyMD beats DocGo on 11 of the 15 factors compared between the two stocks.

How does DocGo compare to Biodesix?

DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

: 56.4% of DocGo shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 3.8% of DocGo shares are held by insiders. Comparatively, 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Biodesix has a net margin of -33.26% compared to DocGo's net margin of -56.61%. DocGo's return on equity of -34.41% beat Biodesix's return on equity.
Company Net Margins Return on Equity Return on Assets
DocGo -56.61% -34.41% -23.82%
Biodesix -33.26% -2,101.40% -35.65%
: Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DocGo $322.20M 0.19 -$182.40M -$1.85 N/A
Biodesix $88.50M 1.77 -$35.26M -$4.06 N/A
: DocGo has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
: In the previous week, Biodesix had 7 more articles in the media than DocGo. MarketBeat recorded 9 mentions for Biodesix and 2 mentions for DocGo. Biodesix's average media sentiment score of 0.33 beat DocGo's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DocGo
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biodesix
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
: DocGo currently has a consensus target price of $2.38, indicating a potential upside of 274.66%. Biodesix has a consensus target price of $33.00, indicating a potential upside of 113.32%. Given DocGo's higher probable upside, equities analysts plainly believe DocGo is more favorable than Biodesix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DocGo
1 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.29
Biodesix
1 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-56.61%	-34.41%	-23.82%
Biodesix	-33.26%	-2,101.40%	-35.65%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.19	-$182.40M	-$1.85	N/A
Biodesix	$88.50M	1.77	-$35.26M	-$4.06	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodesix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Biodesix	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

DocGo and Biodesix tied by winning 8 of the 16 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.42M	$8.15B	$6.31B	$12.15B
Dividend Yield	N/A	2.92%	2.78%	5.25%
P/E Ratio	-0.34	22.49	28.45	27.01
Price / Sales	0.19	17.83	528.56	76.85
Price / Cash	11.24	82.13	43.30	53.97
Price / Book	0.50	4.83	9.82	6.89
Net Income	-$182.40M	$183.43M	$3.55B	$333.11M
7 Day Performance	N/A	N/A	N/A	0.14%
1 Month Performance	15.30%	5.72%	5.20%	6.79%
1 Year Performance	-72.74%	1.71%	40.39%	38.93%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	3.3672 of 5 stars	$0.63 +1.9%	$2.38 +274.7%	-73.6%	$61.42M	$322.20M	N/A	3,568	Upcoming Earnings
LFMD LifeMD	3.5545 of 5 stars	$4.98 +6.3%	$9.14 +83.8%	-44.1%	$239.13M	$194.05M	19.17	230	Trending News Earnings Report
AIRS AirSculpt Technologies	2.1409 of 5 stars	$3.31 +23.3%	$6.00 +81.5%	+35.2%	$232.45M	$151.82M	N/A	240
BNR Burning Rock Biotech	1.1461 of 5 stars	$17.44 +2.6%	N/A	+614.7%	$187.65M	$77.16M	N/A	1,390
NAKA KindlyMD	4.1119 of 5 stars	$0.19 +9.9%	$0.75 +287.6%	N/A	$133.52M	$1.82M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors